New combo therapy shows promise against liver metastases in colorectal cancer
NCT ID NCT02837263
First seen May 01, 2026 · Last updated May 08, 2026 · Updated 2 times
Summary
This early-phase study tested the safety of combining the immunotherapy drug pembrolizumab with targeted radiation (SBRT) in 15 adults with colorectal cancer that had spread only to the liver. After surgery to remove all visible tumors, participants received the combination to see if it could prevent the cancer from coming back within one year. The goal was to find a tolerable treatment that delays or stops recurrence.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, 53792, United States
Conditions
Explore the condition pages connected to this study.